NF-κB activation in development and progression of cancer

Cancer Science

Volumn 98, Issue 3, 2007, Pages 268-274

  Inoue, Jun Ichiro ^a   Gohda, Jin ^a   Akiyama, Taishin ^a   Semba, Kentaro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; CYTOTOXIC AGENT; GROWTH FACTOR; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR INHIBITOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

BONE METASTASIS; BONE REMODELING; CANCER; CANCER CELL; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL ACTIVATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; ENHANCER REGION; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENETIC CODE; INNATE IMMUNITY; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; NONHUMAN; OSTEOCLAST; PRECANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SKIN APPENDAGE; T CELL LEUKEMIA; BINDING SITE; BIOLOGICAL MODEL; DISEASE COURSE; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY;

BINDING SITES; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 33846685017     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00389.x     Document Type: Review

References (62)

1. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10.
2. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8.
3. Yamamoto M, Yamazaki S, Uematsu S et al. Regulation of Toll/IL- 1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature 2004; 430: 218-22.
4. Kuwata H, Matsumoto M, Atarashi K et al. IkappaBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. Immunity 2006; 24: 41-51.
5. Bours V, Franzoso G, Azarenko V et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 1993; 72: 729-39.
6. Ghosh S, Gifford AM, Riviere LR, Tempst P, Nolan GP, Baltimore D. Cloning of the p50 DNA binding subunit of NF-κ B: Homology to rel and dorsal. Cell 1990; 62: 1019-29.
7. Kieran M, Blank V, Logeat F et al. The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell 1990; 62: 1007-18.
8. Neri A, Chang CC, Lombardi L et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 1991; 67: 1075-87.
9. Kim JH, Kim B, Cai L et al. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 2005; 434: 921-6.
10. Karin M, Greten FR. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59.
11. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001; 7: 401-9.
12. Inoue J, Ishida T, Tsukamoto N et al. Tumor necrosis factor receptor-associated factor (TRAF) family: Adapter proteins that mediate cytokine signaling. Exp Cell Res 2000; 254: 14-24.
13. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003; 278: 36 005-12.
14. Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004; 21: 629-42.
15. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004; 279: 26 243-50.
16. Ishida TK, Tojo T, Aoki T et al. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 1996; 93: 9437-42.
17. Ishida T, Mizushima S, Azuma S et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996; 271: 28 745-8.
18. Akiyama T, Maeda S, Yamane S et al. Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science 2005; 308: 248-51.
19. Gohda J, Matsumura T, Inoue J. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF) -dependent pathway in TLR signaling. J Immunol 2004; 173: 2913-7.
20. Gohda J, Akiyama T, Koga T, Takayanagi H, Tanaka S, Inoue J. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 2005; 24: 790-9.
21. Naito A, Azuma S, Tanaka S et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999; 4: 353-62.
22. Naito A, Yoshida H, Nishioka E et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia. Proc Natl Acad Sci USA 2002; 99: 8766-71.
23. Kobayashi N, Kadono Y, Naito A et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J, 2001; 20: 1271-80.
24. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 1996; 383: 443-6.
25. Deng L, Wang C, Spencer E et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-61.
26. Kanayama A, Seth RB, Sun L et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 2004; 15: 535-48.
27. Wertz IE, O'Rourke KM, Zhou H et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430: 694-9.
28. Greten FR, Eckmann L, Greten TF et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
29. Pikarsky E, Porat RM, Stein I et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
30. Tada K, Okazaki T, Sakon S et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J Biol Chem 2001; 276: 36 530-4.
31. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 2003; 115: 565-76.
32. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-90.
33. Neri A, Fracchiolla NS, Roscetti E et al. Molecular analysis of cutaneous B- and T-cell lymphomas. Blood 1995; 86: 3160-72.
34. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117: 979-87; quiz 988.
35. Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006; 16: 32-7.
36. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 1999; 18: 6925-37.
37. Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 1990; 60: 991-7.
38. Caamano JH, Perez P, Lira SA, Bravo R. Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Mol Cell Biol 1996; 16: 1342-8.
39. Willis TG, Jadayel DM, Du MQ et al. Bcl10 is involved in t(1; 14) (p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35-45.
40. Akagi T, Motegi M, Tamura A et al. A novel gene, MALT1 at 18q21, is involved in t (11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18: 5785-94.
41. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-6.
42. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64.
43. Sasaki A, Boyce BF, Story B et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 3551-7.
44. Lomaga MA, Yeh WC, Sarosi I et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13: 1015-24.
45. Ikeda F, Nishimura R, Matsubara T et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004; 114: 475-84.
46. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3: 1285-9.
47. Tsukamoto N, Kobayashi N, Azuma S, Yamamoto T, Inoue J. Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40. Proc Natl Acad Sci USA 1999; 96: 1234-9.
48. Sun SC, Yamaoka S. Activation of NF-kappaB by HTLV-I and implications for cell transformation. Oncogene 2005; 24: 5952-64.
49. Grassmann R, Aboud M, Jeang KT. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005; 24: 5976-85.
50. Algarte M, Lecine P, Costello R, Plet A, Olive D, Imbert J. In vivo regulation of interleukin-2 receptor alpha gene transcription by the coordinated binding of constitutive and inducible factors in human primary T cells. EMBO J 1995; 14: 5060-72.
51. Robek MD, Ratner L. Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J Virol 1999; 73: 4856-65.
52. Yamaoka S, Courtois G, Bessia C et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998; 93: 1231-40.
53. Jeang KT, Widen SG, Semmes Ojt, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990; 247: 1082-4.
54. Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 2004; 104: 1490-7.
55. Carter RS, Geyer BC, Xie M, Acevedo-Suarez CA, Ballard DW. Persistent activation of NF-kappa B by the tax transforming protein involves chronic phosphorylation of IkappaB kinase subunits IKKbeta and IKKgamma. J Biol Chem 2001; 276: 24 445-8.
56. Carter RS, Pennington KN, Arrate P, Oltz EM, Ballard DW. Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates its phosphorylation and persistent activation. J Biol Chem 2005; 280: 43 272-9.
57. Lamsoul I, Lodewick J, Lebrun S et al. Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappaB activation by the human T-cell leukemia virus tax oncoprotein. Mol Cell Biol 2005; 25: 10 391-406.
58. Tamiya S, Matsuoka M, Etoh K et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996; 88: 3065-73.
59. Koiwa T, Hamano-Usami A, Ishida T et al. 5′-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J Virol 2002; 76: 9389-97.
60. Watanabe M, Ohsugi T, Shoda M et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005; 106: 2462-71.
61. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.
62. Pikarsky E, Ben-Neriah Y. NF-kappaB inhibition: A double-edged sword in cancer? Eur J Cancer 2006; 42: 779-84.